Kolette D. Fly

618 total citations
15 papers, 460 citations indexed

About

Kolette D. Fly is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology. According to data from OpenAlex, Kolette D. Fly has authored 15 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Gastroenterology. Recurrent topics in Kolette D. Fly's work include Gastrointestinal Tumor Research and Treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (4 papers). Kolette D. Fly is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (4 papers). Kolette D. Fly collaborates with scholars based in United States, Germany and Italy. Kolette D. Fly's co-authors include Ewa Matczak, Carlos H. Barrios, Ronald M. Bukowski, Xun Lin, Bernard Escudier, Martin Gore, Thomas E. Hutson, Brian I. Rini, Robert J. Motzer and George D. Demetri and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Kolette D. Fly

15 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kolette D. Fly United States 8 233 179 120 93 79 15 460
Joanna Gale United Kingdom 8 323 1.4× 143 0.8× 152 1.3× 52 0.6× 33 0.4× 22 641
Matthew Robson Japan 6 327 1.4× 283 1.6× 46 0.4× 236 2.5× 23 0.3× 13 561
Yanzhi Hsu United States 16 429 1.8× 340 1.9× 199 1.7× 108 1.2× 79 1.0× 42 891
Valerie Poulart United States 13 283 1.2× 684 3.8× 51 0.4× 116 1.2× 59 0.7× 17 1.0k
Joseph Gibbons United States 10 180 0.8× 193 1.1× 34 0.3× 102 1.1× 81 1.0× 17 491
K Miwa Japan 18 426 1.8× 285 1.6× 248 2.1× 178 1.9× 29 0.4× 44 866
Paola Coco Italy 12 420 1.8× 143 0.8× 359 3.0× 98 1.1× 64 0.8× 22 651
M.C. Cox United States 10 177 0.8× 180 1.0× 14 0.1× 91 1.0× 50 0.6× 23 429
Marilyn Mulay United States 11 250 1.1× 365 2.0× 32 0.3× 243 2.6× 37 0.5× 17 644
So Young Rha South Korea 5 111 0.5× 181 1.0× 35 0.3× 151 1.6× 15 0.2× 8 433

Countries citing papers authored by Kolette D. Fly

Since Specialization
Citations

This map shows the geographic impact of Kolette D. Fly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kolette D. Fly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kolette D. Fly more than expected).

Fields of papers citing papers by Kolette D. Fly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kolette D. Fly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kolette D. Fly. The network helps show where Kolette D. Fly may publish in the future.

Co-authorship network of co-authors of Kolette D. Fly

This figure shows the co-authorship network connecting the top 25 collaborators of Kolette D. Fly. A scholar is included among the top collaborators of Kolette D. Fly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kolette D. Fly. Kolette D. Fly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Hong, David S., Ajay K. Gopal, Alexander N. Shoushtari, et al.. (2022). Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Frontiers in Immunology. 13. 897991–897991. 17 indexed citations
2.
Gopal, Ajay K., Ronald Levy, Roch Houot, et al.. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research. 26(11). 2524–2534. 45 indexed citations
3.
Chen, Robert W., Stephen M. Ansell, Pier Luigi Zinzani, et al.. (2017). Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology. 35(15_suppl). TPS7575–TPS7575. 3 indexed citations
4.
Reichardt, Peter, George D. Demetri, Hans Gelderblom, et al.. (2016). Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 16(1). 22–22. 53 indexed citations
5.
Cortes, Jörge E., H. Jean Khoury, Hagop M. Kantarjian, et al.. (2016). Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib. American Journal of Hematology. 91(6). 606–616. 70 indexed citations
6.
Reichardt, Peter, Yoon‐Koo Kang, Piotr Rutkowski, et al.. (2015). Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib. Cancer. 121(9). 1405–1413. 85 indexed citations
7.
Cortes, Jörge E., Hagop M. Kantarjian, H. Jean Khoury, et al.. (2014). Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib.. Journal of Clinical Oncology. 32(15_suppl). 7060–7060. 13 indexed citations
8.
Reichardt, Peter, George D. Demetri, Hans Gelderblom, et al.. (2014). Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. Journal of Clinical Oncology. 32(15_suppl). 10549–10549. 1 indexed citations
9.
Motzer, Robert J., Bernard Escudier, Ronald M. Bukowski, et al.. (2013). Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. British Journal of Cancer. 108(12). 2470–2477. 108 indexed citations
10.
Reichardt, Peter, Yoon‐Koo Kang, Piotr Rutkowski, et al.. (2012). Continued Sunitinib Treatment After Progressive Disease (PD) in a Worldwide Treatment-Use Trial of Patients (PTS) With Gastrointestinal Stromal Tumor (GIST). Annals of Oncology. 23. ix482–ix482. 3 indexed citations
11.
Aglietta, Massimo, C. Barone, Malcolm J. Moore, et al.. (2011). Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer.. Journal of Clinical Oncology. 29(15_suppl). 4081–4081. 4 indexed citations
12.
Reichardt, Peter, Yiming Kang, Piotr Rutkowski, et al.. (2011). 9421 POSTER Optimizing Management of Sunitinib Treatment in a Worldwide Treatment-use Trial of Patients (Pts) With Advanced Gastrointestinal Stromal Tumour (GIST). European Journal of Cancer. 47. S669–S669. 2 indexed citations
13.
Aglietta, Massimo, C. Barone, Cinzia Bagalá, et al.. (2010). A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer.. Journal of Clinical Oncology. 28(15_suppl). 4134–4134. 5 indexed citations
14.
Beatty, Gregory L., E. Gabriela Chiorean, Drew A. Torigian, et al.. (2010). A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.. Journal of Clinical Oncology. 28(15_suppl). 2539–2539. 1 indexed citations
15.
Buzdar, Aman U., Daniel F. Hayes, Shunchao Yan, et al.. (2002). Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 73(2). 161–175. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joanna Gale Breakdown of academic impact, for papers by Matthew Robson Breakdown of academic impact, for papers by Yanzhi Hsu Breakdown of academic impact, for papers by Valerie Poulart Breakdown of academic impact, for papers by Joseph Gibbons Breakdown of academic impact, for papers by K Miwa Breakdown of academic impact, for papers by Paola Coco Breakdown of academic impact, for papers by M.C. Cox Breakdown of academic impact, for papers by Marilyn Mulay Breakdown of academic impact, for papers by So Young Rha
Rankless by CCL
2026